Automated Insulin Delivery Systems: The Future of Diabetes Care

Imagine if your insulin pump could automatically adjust your basal insulin based on your blood sugar—no manual input required.

That's the promise of automated insulin delivery (AID) systems, also called hybrid closed-loop systems or the "artificial pancreas."

Once considered science fiction, these systems are now FDA-approved and transforming diabetes management. The 2025 ADA guidelines recognize AID as the most effective method currently available for managing type 1 diabetes.

---

What Is Automated Insulin Delivery?

The Concept

AID systems combine three technologies:

How It Works

CGM reads glucose → Algorithm predicts future glucose →
Pump automatically increases/decreases basal insulin →
Glucose stabilizes

Key insight: The system acts like a healthy pancreas—constantly adjusting to maintain target glucose.

---

Levels of Automation

Threshold Suspend (Low Glucose Suspend)

Example: Medtronic 670G/770G SmartGuard feature

Predictive Low Glucose Management

Examples: Medtronic 770G, Tandem Basal-IQ

Hybrid Closed Loop (HCL)

Examples: Tandem Control-IQ, Omnipod 5 with Horizon, CamAPS FX

Full Closed Loop (Future)

Status: Full closed loop in clinical trials; not yet FDA-approved for commercial use.

---

Available AID Systems

Tandem Control-IQ (t:slim X2)

Medtronic 770G

Insulet Omnipod 5 with Horizon

CamAPS FX (Worldwide)

iLet (Beta Bionics)

---

The Evidence: How Well Does AID Work?

Clinical Trial Results

Interpretation: AID systems improve Time in Range by 10-20 percentage points while significantly reducing hypoglycemia.

Compared to Standard Therapy

---

Benefits of AID Systems

For Users

For Families

---

Limitations of Current Systems

Still "Hybrid" Closed Loop

Technical Considerations

---

Getting Started with AID

Eligibility

Preparation

---

The Future: What's Next?

Fully Automated "Bionic Pancreas"

iLet (Beta Bionics):

• Bi-hormonal (insulin AND glucagon)
• Fully automated basal and meal bolus
• FDA submission (as of 2024)

Implantable AID:

• Fully implantable pump + sensor
• No external devices
• Refill procedure every few months
• In clinical trials

Algorithm Improvements

---

Costs and Coverage

System Costs

Insurance Coverage

---

Real-World Experiences

User Perspectives

What users like:

• Fewer nighttime lows
• Better sleep
• Less worry about glucose swings
• Flexibility with exercise and meals

What users find challenging:

• Still need to bolus for meals | Alarm fatigue (beeping at night) | | Device management (charging, changing sensors) | | Expectations vs reality (not fully automated yet) |

Success Factors

---

Special Populations

Pregnancy

AID shows promise for pregnancy:

Note: AID is not yet FDA-approved for pregnancy but is increasingly used off-label.

Young Children

Older Adults

---

Key Takeaways

1. AID systems combine CGM + pump + algorithm for automated insulin delivery
2. Hybrid closed-loop is currently available; fully automated coming soon
3. Time in Range improves 10-20 percentage points with AID
4. Hypoglycemia significantly reduced—especially overnight
5. User still needs to bolus for meals (carb counting still required)
6. Multiple systems available: Tandem Control-IQ, Medtronic 770G, Omnipod 5
7. Future is fully automated "bionic pancreas" with insulin + glucagon

---

FAQ Section

What is an automated insulin delivery system?

An AID system combines a CGM, insulin pump, and control algorithm to automatically adjust basal insulin based on glucose levels. Current systems are "hybrid" closed-loop, meaning they automatically adjust basal insulin but still require the user to bolus for meals.

How does a hybrid closed-loop system work?

A hybrid closed-loop system uses CGM data to predict future glucose levels (typically 30 minutes ahead). Based on this prediction, it automatically increases basal insulin when glucose is rising or decreasing/stop basal when glucose is falling. The user still announces meals and delivers insulin boluses.

Is an artificial pancreas available?

Yes and no. Several "artificial pancreas" or AID systems are FDA-approved and available (Tandem Control-IQ, Medtronic 770G, Omnipod Horizon). These are "hybrid" systems that require user input for meals. Fully automated systems that also deliver mealtime insulin are in development.

Does AID eliminate hypoglycemia?

No, but AID significantly reduces hypoglycemia. Clinical trials show time below 70 mg/dL is reduced by 30-50%. The predictive algorithms can suspend insulin before hypoglycemia occurs, providing an important safety buffer.

Can anyone with diabetes get an AID system?

AID systems are approved for people with type 1 diabetes (or insulin-deficient type 2) typically ≥ 2 years old (age varies by system). Insurance coverage may require documentation of medical need (A1C not at goal, frequent hypoglycemia). The user must be willing to wear CGM and engage with the technology.

---

Sources:

• American Diabetes Association. Standards of Care in Diabetes—2025. Diabetes Care 2025; 48(Suppl 1)
• Brown SA, et al. Diabetes Care 2019;42(Suppl 2):S233-S244 (AID consensus)
• Tandem Diabetes Control-IQ

---

Medical Disclaimer

This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about your health, treatment, or care. Individual circumstances vary, and what is appropriate for one person may not be appropriate for another.

If you are experiencing a medical emergency, call 911 (or your local emergency number) immediately.